Immunome's Varegacestat Shows Positive Phase 3 Results in Desmoid Tumors

Immunome announced positive topline results from its Phase 3 RINGSIDE trial of varegacestat in patients with desmoid tumors. The trial met its primary endpoint, demonstrating an 84% reduction in the risk of disease progression or death versus placebo.